• Molecular NameMaraviroc
  • Synonymmaraviroc
  • Weight513.677
  • Drugbank_IDDB04835
  • ACS_NO376348-65-1
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)5.39
  • pka3.3; 7.9
  • LogD (pH=7, predicted)3.27
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-2.62
  • LogSw (predicted, AB/LogsW2.0)0.04
  • Sw (mg/ml) (predicted, ACD/Labs)0.02
  • No.of HBond Donors1
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds8
  • TPSA63.05
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA drug used in the treatment of HIV infection.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability23.0
  • Protein binding75.5
  • Volume of distribution (VD)194 L
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmStudies in humans and in vitro studies using human liver microsomes and expressed enzymes have demonstrated that maraviroc is principally metabolized by the cytochrome P450 system to metabolites that are essentially inactive against HIV-1. In vitro studies indicate that CYP3A is the major enzyme responsible for maraviroc metabolism
  • Half life16 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe most common adverse events reported with SELZENTRY twice daily therapy with frequency rates higher than placebo, regardless of causality, were cough, pyrexia, upper respiratory tract infections, rash, musculoskeletal symptoms, abdominal pain and dizziness.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A